

REFERENCES

- Abramson, N., & Melton, B. (2000). Leukocytosis: basics of clinical assessment. *American family physician*, 62(9), 2053-2060.
- Adamu, A. L., Crampin, A., Kayuni, N., Amberbir, A., Koole, O., Phiri, A., et al. (2017). Prevalence and risk factors for anemia severity and type in Malawian men and women: urban and rural differences. *Population health metrics*, 15(1), 12.
- Anthony, M. L., Chandra, H., Gupta, A., Nath, U. K., & Singh, A. (2019). Splenic Marginal Zone Lymphoma: A Case with Long History. *Journal of Clinical & Diagnostic Research*, 13(12).
- Asmara, I. (2018). Penanda Biologis Limfoma Maligna. *Jurnal Kedokteran Unram*, 7(4), 40-48.
- Birgegard G, Gascon P, Ludwig H. (2006). Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. *Eur J Haematol*. 77(5):378–86. doi: 10.1111/j.1600-0609.2006.00739.x.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R., Torre, L., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 68(6).
- Burger, R. (2013). Impact of interleukin-6 in hematological malignancies. *Transfusion Medicine and Hemotherapy*, 40(5), 336-343.
- Cannavale, K., Xu, H., Xu, L., Sattayapiwat, O., Rodriguez, R., Bohac, C., Page, J., & Chao, C. (2019). Epidemiology of Chemotherapy-Induced Anemia in Patients with Non-Hodgkin's Lymphoma. *The Permanente journal*, 23, 18-252. <https://doi.org/10.7812/TPP/18-252>
- Chaparro, C.M., Suchdev, P.S. (2019). Anemia epidemiology, pathophysiology and etiology in low- and middle-income countries. *Ann N Y Acad Sci*, 1450, pp. 15–31.
- Chihara, D., Nastoupil, L., Williams, J., Lee, P., Koff, J., & Flowers, C. (2015). New insights into the epidemiology of non-Hodgkin's lymphoma and implications for therapy [see comments]. *Expert Rev Anticancer Ther. Author manuscript*, 15(5), 531-544.
- Ciesla, B. (2018). *Hematology in practice*. FA Davis.
- Devitt, K. A., Lunde, J. H., & Lewis, M. R. (2014). New onset pancytopenia in adults: a review of underlying pathologies and their associated clinical and laboratory findings. *Leukemia & lymphoma*, 55(5), 1099-1105.
- Diumenjo, M.C., Abriata, G., Forman, D., Sierra, M.S. (2016). Etiology of non-Hodgkin's lymphoma (C82–85, C96) in Central and South America. *Cancer in Central and South America*. Lyon: International Agency for Research on Cancer.

- Djurasinovic V, Sipetic-Grujicic S, Antic D, Vukovic V, Bila J, et al. (2018). The Nutritional Status of Patients with Diffuse Large B cell Lymphoma Does it Matter?. *J Nutri Health*. 4(2): 4
- Ekström Smedby, K., Vajdic, C.M., Falster, M., Engels, E.A., Martínez-Maza, O., Turner, J., et al. (2008). Autoimmune disorders and risk of non-Hodgkin's lymphoma subtypes: a pooled analysis within the InterLymph Consortium. *Blood*. 111(8):4029–38.
- GLOBOCAN. (2018). *Asia Fact Sheets*. The Global Cancer Observatory
- GLOBOCAN. (2018). *Indonesia Fact Sheets*. The Global Cancer Observatory.
- Goldman, L., & Schafer, A. I. (2011). *Goldman's cecil medicine E-book*. Elsevier Health Sciences.
- Gomes, M.M., Oliva, T. and Pinto, A., (2016). Autoimmune Hemolytic Anemia and Hodgkin's Disease: An Unusual Pediatric Association, *Case Rep Pediatr*, 2016:4598587
- Goodman, C. C., & Fuller, K. S. (2016). *Pathology for the Physical Therapist Assistant-E-Book*. Elsevier Health Sciences.
- Guyton, K. Z., Loomis, D., Grosse, Y., El Ghissassi, F., Benbrahim-Tallaa, L., Guha, N., et al. (2015). International Agency for Research on Cancer Monograph Working Group, IARC, Lyon, France. Carcinogenicity of tetrachlorvinphos, parathion, malathion, diazinon and glyphosate. *Lancet Oncol*. 16(5):490–1.
- Haïoun, C., Salar, A., Pettengell, R., Erik Johnsen, H., Duehrsen, U., Gaia Rossi, F., et al. (2011). Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin's lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisolone±rituximab chemotherapy: results from an observational study. *Leukemia & lymphoma*, 52(5), 796-803.
- Han, X., Stevens, J., & Bradshaw, P. T. (2013). Body mass index, weight change and survival in non-Hodgkin lymphoma patients in Connecticut women. *Nutrition and cancer*, 65(1), 43-50.
- Hauswirth, A. W., Skrabs, C., Schützinger, C., Raderer, M., Chott, A., Valent, P., et al. (2008). Autoimmune thrombocytopenia in non-Hodgkin's lymphomas. *Haematologica*, 93(3), 447-450.
- Hohaus, S., Massini, G., Giachelia, M., Vannata, B., Bozzoli, V., Cuccaro, A., D'Alo, F., Larocca, L.M., Raymakers, R.A., Swinkels, D.W. and Voso, M.T. (2010). Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. *J Clin Oncol*, 28(15), pp. 2538-2543.
- Hong, J., Woo, H. S., Kim, H., Ahn, H. K., Sym, S. J., Park, J., et al. (2014). Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy. *Cancer Science*, 105(12), 1569-1575.
- Horesh, N., & Horowitz, N. A. (2014). Does gender matter in non-Hodgkin lymphoma? Differences in epidemiology, clinical behavior and therapy. *Rambam Maimonides medical journal*, 5(4).

- International Non-Hodgkin's Lymphoma Prognostic Factors Project. (1993). A predictive model for aggressive non-Hodgkin's lymphoma. *New England Journal of Medicine*, 329(14), 987-994.
- Jaffe, E. S. (Ed.). (2001). *Pathology and genetics of tumors of hematopoietic and lymphoid tissues* (Vol. 3). Iarc.
- Jun, S., Siguo, H., Bobin, C., et al. (2020). Investigasi dan analisis anemia pada pasien dengan limfoma multicenter di Shanghai. *J Chinese Journal of Hematology*. 41 (02): 123-127. DOI: 10.3760 / cma.j .issn.0253-2727.2020.02.007
- Kelly, C. M., & Shahrokni, A. (2016). Moving beyond Karnofsky and ECOG performance status assessments with new technologies. *Journal of oncology*, 2016.
- Kementrian Kesehatan RI. (2015). *Data dan Kondisi Penyakit Limfoma di Indonesia*. Pusat Data dan Informasi Kementrian Kesehatan RI.
- Khan, Z. A., Khan, T., Bhardwaj, A., Aziz, S. J., & Sharma, S. (2018). Underweight as a risk factor for nutritional anaemia-a cross-sectional study among undergraduate students of a medical college of Haryana. *Indian Journal of Community Health*, 30(1).
- Khanna, G. (2016). *Concise Pathology for Exam Preparation-E-Book*. Elsevier Health Sciences.
- Laurent, C., Do, C., Gourraud, P. A., de Paiva, G. R., Valmary, S., & Brousset, P. (2015). Prevalence of common non-Hodgkin lymphomas and subtypes of Hodgkin lymphoma by nodal site of involvement: a systematic retrospective review of 938 cases. *Medicine*. 94(25).
- Lymphoma Research Foundation, (2017). *Understanding Non-Hodgkin's Lymphoma*. s.l.:s.n.
- Matsumoto, K., Fujisawa, S. ando, T., Koyama, M., Koyama, S., Ishii, Y., et al. (2018). Anemia associated with worse outcome in diffuse large B-Cell lymphoma patients: a single-center retrospective study. *Turkish Journal of Hematology*, 35(3), 181.
- Morrow, T. J., Volpe, S., Gupta, S., Tannous, R. E., & Fridman, M. (2002). Anemia of cancer in intermediate-grade non-Hodgkin's lymphoma. *SOUTHERN MEDICAL JOURNAL-BIRMINGHAM ALABAMA-*, 95(8), 889-896.
- Nair, R., Kakroo, A., Bapna, A., Gogia, A., & Korula, A., et al. (2018). Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group. *Indian J Hematol Blood Transfus*.
- Najafi, S., Payandeh, M., & Sadeghi, M. (2017). Clinicopathology Figures and Survival of Non-Hodgkin's Lymphoma in Iran. *Iranian Journal of Cancer Prevention*. 10 (1); e5226
- Nogai, H., Dorken, B., & Lenz, G. (2011). Pathogenesis of Non-Hodgkin's Lymphoma. *Journal of Clinical Oncology*, 29(14), 1803-1809.

- Paes, F. M., Kalkanis, D. G., Sideras, P. A., & Serafini, A. N. (2010). FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. *Radiographics*, 30(1), 269-291.
- Paramartha, I. K. A., & RA, R. (2017). Karakteristik pasien limfoma maligna di RSUP Sanglah tahun 2015. *J Med Udayana*, 6(2), 1-9.
- Power, C., Kuh, D., & Morton, S. (2013). From developmental origins of adult disease to life course research on adult disease and aging: insights from birth cohort studies. *Annual review of public health*, 34.
- Prasad, S., Sung, B., & Aggarwal, B. B. (2012). Age-associated chronic diseases require age-old medicine: role of chronic inflammation. *Preventive medicine*, 54, S29-S37.
- Qin, Y., Melse-Boonstra, A., Pan, X., Yuan, B., Dai, Y., Zhao, J., Zimmermann, M.B., Kok, F.J., Zhou, M., Shi, Z. (2013). Anemia in relation to body mass index and waist circumference among chinese women. *Nutr J*, 12, pp. 10.
- Reksodiputro, A. H. (2015). Multicentre Epidemiology and Survival Study of B Cell Non Hodgkin Lymphoma Patients In Indonesia. *J Blood Disorders. Transf* 6: 257. doi: 10.4172/2155-9864.1000257.
- Rochet, N. M., Markovic, S. N., & Porrata, L. F. (2012). The Role of Complete Blood Cell Count in Prognosis—Watch this Space!. *Journal-The Role of Complete Blood Cell Count in Prognosis—Watch this Space!*.
- Salma, R. S., Sedana, M. P., & Yudho, S. U. (2018). CHOP and R-CHOP Therapeutic Responses in Non-Hodgkin Lymphoma Patients in Dr. Soetomo General Hospital Surabaya. *Biomolecular and Health Science Journal*, 1(2), 93-96.
- Sapkota, S., & Shaikh, H. (2020). Non-Hodgkin Lymphoma. *StatPearls [Internet]*.
- Sehn, L. H. (Ed.). (2015). Introduction to a clinical review series on aggressive B-Cell lymphoma. *Blood Journal*, 125: 1.
- Sehn, L. H. (Ed.). (2016). Introduction to a review series: the paradox of indolent B-Cell lymphoma. *Blood Journal*, 127: 17.
- Sehn, L. H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., et al. (2007). The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-Cell lymphoma treated with R-CHOP. *Blood*, 109(5), 1857-1861.
- Singh, Rajeshwar, P. Dubey, A., Rathore, A., Rajan, K., Sharma, D., Kumar Singh, N., & Maggo, S. (2018). Diffuse Large B-Cell Lymphoma-Review. *Journal of Medical Sciences*, 38: 137-143.
- Stopeck, A. T., Unger, J. M., Rimsza, L. M., LeBlanc, M., Farnsworth, B., Iannone, M., ... & Miller, T. P. (2012). A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. *Blood, The Journal of the American Society of Hematology*, 120(6), 1210-1217.
- Suryadiarsa, I. P. D. P., Rena, N. M. R. A., & Dharmayuda, T. G. TINGKAT HARAPAN HIDUP PASIEN LIMFOMA NON-HODGKIN BERDASARKAN

SKOR IPI YANG MENDAPATKAN KEMOTERAPI LINI PERTAMA DI
RSUP SANGLAH DENPASAR TAHUN 2014.

- Swerlow, Steven H., Campo, E., Pileri, S. A., Harris, Nancy L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz andrew D., Jaffe E. S. (2016). The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood Journal*, 127:20.
- Tisi, M.C., Bozzoli, V., Giachelia, M., Massini, G., Ricerca, B.M., Maiolo, E., et al. (2014). Anemia in diffuse large B-Cell non-Hodgkin's lymphoma: The role of interleukin-6, hepcidin and erythropoietin, *Leuk. Lymphoma*, 55:270–275.
- Tracy, S., Larson, M., Feldman, A., Maurer, M., Slager, S., Villasboas, J., & Cerhan, J., et al. (2019). The utility of prognostic indices, early events and histological subtypes on predicting outcomes in non-follicular indolent B-Cell lymphomas. *American Journal of Haematology*, 94(6).
- Turner, J., Parsi, M. & Badireddy, M. (2020). Anemia. *Treasure Island: StatPearls Publishing*.
- Wahlin, B. E., Yri, O. E., Kimby, E., Holte, H., Delabie, J., Smeland, E. B., et al. (2012). Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. *British journal of haematology*, 156(2), 225-233.
- Weinzierl, E. P., & Arber, D. A. (2013). The differential diagnosis and bone marrow evaluation of new-onset pancytopenia. *American journal of clinical pathology*, 139(1), 9-29.
- Wilcox, R. A., Ristow, K., Habermann, T. M., Inwards, D. J., Micallef, I. N. M., Johnston, P. B., et al. (2011). The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. *Leukemia*, 25(9), 1502-1509.
- Winarto, D., Rena, N. M. R. A., Adnyana, W. L., Dharmayuda, T. G., Suega, K., & Bakta, I. M. (2018). Kadar hemoglobin awal sebagai faktor prognostik penderita limfoma non-hodgkin (LNH) yang menjalani kemoterapi. *Jurnal Penyakit Dalam Udayana*, 2(2), 38-43.
- Yasmeen, T., Ali, J., Khan, K., & Siddiqui, N. (2019). Frequency and causes of anemia in Lymphoma patients. *Pakistan Journal of Medical Sciences*, 35(1):61-65. doi: 10.12669/pjms.35.1.91
- Ziepert, M., Hasenclever, D., Kuhnt, E., Glass, B., Schmitz, N., Pfreundschuh, M., & Loeffler, M. (2010). Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-Cell lymphoma in the rituximab era. *Journal of clinical oncology*, 28(14), 2373-2380.
- Znaor, A., Piñeros, M., Miranda-Filho, A., Marcos-Gragera, R., Steliarova-Foucher, E., & Bray, F. (2019). Global patterns and trends in the incidence of non-Hodgkin's lymphoma. *Cancer Causes and Control*, 30(15), 489-499.